You are viewing: UK Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The UK Leukapheresis Market was valued at $5.13 Million in 2026 and projected to reach to $7.55 Million by 2031, representing a compound annual growth rate of 8.0%. The UK leukapheresis market is positioned for steady growth driven by the expanding adoption of cell therapy treatments and increasing prevalence of hematologic malignancies.

UK Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Leukapheresis Market Trends and Insights

  • The UK market benefits from advanced healthcare infrastructure, increasing adoption of cell therapy treatments, and rising prevalence of hematologic malignancies requiring leukapheresis procedures.
  • The UK's established regulatory framework and NHS support for innovative cancer therapies are driving demand for leukapheresis equipment and services across major medical centers. Growth in the UK leukapheresis market is underpinned by expanding clinical applications in CAR-T cell therapy and other immunotherapies, coupled with growing patient awareness and physician adoption.
  • The UK's commitment to precision medicine and investment in oncology infrastructure further supports market expansion through 2031.
  • Key healthcare providers and private clinics in the UK are increasingly integrating leukapheresis capabilities to meet rising treatment demand..

Key Market Statistics

  • CAGR (2026-2031) 8.0% CAGR
  • Market Size, 2026 ~USD 5.13 Million
  • Forecast, 2031 ~USD 7.55 Million
  • Country UK

UK Leukapheresis Market Overview

Market Size & Growth :

The UK leukapheresis market is valued at £5.13 million in 2026 and is projected to reach £7.55 million by 2031, with a steady CAGR of 8.0% over the forecast period.

Advanced Healthcare Infrastructure :

The UK's robust NHS framework and private healthcare sector provide strong support for leukapheresis adoption, with established clinical protocols and reimbursement pathways facilitating market expansion.

Rising Cell Therapy Demand :

Increasing adoption of CAR-T cell therapies and other advanced cell-based treatments in UK hospitals is driving demand for leukapheresis procedures as a critical first step in treatment protocols.

Hematologic Malignancy Prevalence :

Growing incidence of blood cancers and leukemias in the UK population is creating sustained demand for leukapheresis procedures, supported by improved diagnostic capabilities and treatment accessibility.

UK Leukapheresis Market Dynamics

  • The UK's well-established healthcare infrastructure, combined with NHS support for innovative cancer treatments, creates a favorable environment for market expansion.
  • Regulatory approvals for new cell therapies and growing clinical awareness among UK healthcare providers are expected to accelerate procedure volumes. Looking ahead to 2031, the market will benefit from technological advancements in apheresis equipment, improved patient outcomes driving treatment adoption, and potential expansion of leukapheresis applications beyond oncology.
  • Investment in UK hospital infrastructure and training programs for apheresis specialists will further support market growth, positioning the country as a key hub for cell therapy development in Europe..

Related Ecosystem

Key Takeaways

  • The UK leukapheresis market is valued at £5.13 million in 2026 and will reach £7.55 million by 2031 at an 8.0% CAGR.
  • The UK's advanced healthcare infrastructure and NHS support for cell therapies are primary growth catalysts for the leukapheresis market.
  • Rising prevalence of hematologic malignancies and expanding CAR-T cell therapy adoption are driving UK market demand.
  • The UK leukapheresis market is characterized by increasing integration of procedures across NHS trusts and private oncology centers.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

UK Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers of apheresis equipment and leukapheresis systems need UK market data to assess market opportunity, identify NHS procurement pathways, and develop region-specific product strategies.
  • Healthcare Providers & NHS Trusts : UK hospitals and NHS trusts require market insights to justify capital investments in leukapheresis infrastructure, benchmark service volumes, and plan cell therapy program expansion.
  • Pharmaceutical & Biotech Companies : Cell therapy developers and pharmaceutical firms need UK market analysis to understand treatment adoption rates, identify hospital partners, and forecast commercial potential for CAR-T and other therapies.
  • Healthcare Consultants & Advisors : Management consultants and healthcare advisors use UK market data to support client strategy, investment decisions, and market entry planning for leukapheresis-related services.
  • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in the UK require detailed market analysis to assess growth potential, identify acquisition targets, and evaluate returns in the leukapheresis sector.

Key Companies in the UK Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • UK-Specific Market Sizing : Obtain precise market valuation and forecasts tailored to the UK market, enabling accurate budget allocation and investment decisions for leukapheresis equipment and services.
  • Regulatory & Reimbursement Insights : Understand UK-specific regulatory pathways, NHS reimbursement structures, and clinical commissioning requirements that directly impact market entry and commercial strategy.
  • Competitive Landscape Analysis : Identify key players operating in the UK leukapheresis market, their market share, and strategic positioning to inform competitive strategy and partnership opportunities.
  • Growth Driver Identification : Analyze UK-specific factors driving market growth, including cell therapy adoption rates, hospital infrastructure investments, and disease prevalence trends unique to the British population.
  • Strategic Planning Support : Leverage UK market intelligence to develop targeted go-to-market strategies, identify high-potential hospital networks, and prioritize geographic expansion within the UK healthcare system.

Frequently asked questions

What is the current size of the UK leukapheresis market?

The UK leukapheresis market is estimated at £5.13 million in 2026 and is expected to grow to £7.55 million by 2031.

What is the projected growth rate for the UK leukapheresis market?

The UK leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 8.0% from 2026 to 2031.

What factors are driving growth in the UK leukapheresis market?

Key drivers include increasing adoption of CAR-T cell therapies, rising prevalence of hematologic malignancies, NHS support for innovative cancer treatments, and expansion of oncology infrastructure across the UK.

Which healthcare providers in the UK offer leukapheresis services?

Major NHS trusts and specialized private oncology centers across the UK are increasingly offering leukapheresis services to support cell therapy and immunotherapy treatments.

How does the UK leukapheresis market compare to other European markets?

The UK leukapheresis market, growing at 8.0% CAGR, reflects strong healthcare infrastructure and regulatory support, positioning it as a significant segment within the broader European leukapheresis market.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status